Kazia Therapeutics Files Routine 6-K Report
Ticker: KZIA · Form: 6-K · Filed: Nov 12, 2024 · CIK: 1075880
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Kazia Therapeutics filed a standard 6-K, no new news.
AI Summary
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on November 12, 2024. The filing is a report of a foreign private issuer and does not specify any new material events or financial updates beyond its routine reporting status. The company is incorporated in Australia and its fiscal year ends on June 30.
Why It Matters
This filing indicates Kazia Therapeutics is fulfilling its reporting obligations as a foreign private issuer, but does not contain new operational or financial news.
Risk Assessment
Risk Level: low — This is a routine filing by a foreign private issuer and does not contain any new material information that would immediately impact the company's risk profile.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- 000-29962 (other) — SEC File Number
- 20241112 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. It is used to report information which the issuer makes or is required to make public pursuant to the laws of its home country, or which is made or is required to be made public to any stock exchange on which it has a securities listed, or which is distributed or is required to be distributed to its security holders.
When was Kazia Therapeutics Limited previously known as?
Kazia Therapeutics Limited was formerly known as Novogen Ltd, with a date of name change on December 28, 1998.
What is Kazia Therapeutics Limited's fiscal year end?
Kazia Therapeutics Limited's fiscal year ends on June 30.
Where is Kazia Therapeutics Limited's principal executive office located?
Kazia Therapeutics Limited's principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Does this filing indicate any new financial results or material events?
No, this Form 6-K filing does not specify any new material events or financial updates beyond its routine reporting status as a foreign private issuer.
Filing Stats: 305 words · 1 min read · ~1 pages · Grade level 19.8 · Accepted 2024-11-12 08:12:25
Key Financial Figures
- $1.00 — S, on Nasdaq Capital Market has been at $1.00 per ADS or greater for 10 consecutive b
Filing Documents
- d853396d6k.htm (6-K) — 8KB
- 0001193125-24-255197.txt ( ) — 9KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On November 12, 2024, Kazia Therapeutics Limited (the Company) announced that it received a written notification (the Notification Letter) from the Nasdaq Stock Market, LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement). The Notification Letter confirmed that the closing bid price of the Companys American Depositary Shares (the ADSs), representing 100 ordinary shares of the Company per ADS, on Nasdaq Capital Market has been at $1.00 per ADS or greater for 10 consecutive business days from October 28, 2024 to November 8, 2024 and that the Company has regained compliance with the Minimum Bid Price Requirement. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: November 12, 2024